Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Pharma
Despite trial miss, Bausch + Lomb advances combo to ph. 3
Bausch + Lomb has flunked a phase 2 trial of its combination of dry-eye disease drugs Xiidra and Miebo, but will advance the combo to phase 3.
Kevin Dunleavy
Aug 25, 2026 10:46am
Verily Me, Bausch + Lomb partner up on dry eye education
Aug 6, 2026 9:35pm
Bausch + Lomb doubles down on dry eye awareness push
Jul 1, 2025 11:16am
Alcon gains first FDA prescription drug nod since Novartis split
May 29, 2025 10:20am
Bausch + Lomb taps broadcaster Erin Andrews for dry eye campaign
Oct 8, 2024 10:50am
Bausch + Lomb debuts online resource to boost dry eye awareness
Jul 8, 2024 11:33am
